Published in Hum Vaccin Immunother on January 01, 2015
Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles. Vaccine (2016) 0.77
Neonatal Vaccination: Challenges and Intervention Strategies. Neonatology (2016) 0.77
Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7. Vaccines (Basel) (2016) 0.77
Evaluation of Borrelia burgdorferi BbHtrA Protease as a Vaccine Candidate for Lyme Borreliosis in Mice. PLoS One (2015) 0.75
LigB subunit vaccine confers sterile immunity against challenge in the hamster model of leptospirosis. PLoS Negl Trop Dis (2017) 0.75
Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4. Front Immunol (2017) 0.75
Aluminum (oxy)hydroxide nanosticks synthesized in bicontinuous reverse microemulsion have potent vaccine adjuvant activity. ACS Appl Mater Interfaces (2017) 0.75
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med (2006) 9.73
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature (2008) 9.16
Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol (2005) 7.28
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun (1974) 6.53
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science (2006) 6.47
Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med (2008) 5.42
In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro (2005) 4.47
Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol (2008) 3.66
Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol (2009) 3.51
Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol (2007) 3.17
Some Observations on the Use of Alum Precipitated Diphtheria Toxoid. Am J Public Health Nations Health (1935) 2.93
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med (2011) 2.82
Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74
An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity (2011) 2.57
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol (2009) 2.49
Promotion of B cell immune responses via an alum-induced myeloid cell population. Science (2004) 2.47
DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 2.41
Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine (2007) 2.13
Mechanism of action of clinically approved adjuvants. Curr Opin Immunol (2009) 2.06
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol (1985) 1.88
Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines (2007) 1.86
MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One (2009) 1.79
Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun (1982) 1.73
Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain (2001) 1.67
Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity (2011) 1.65
MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines (2003) 1.64
(How) do aluminium adjuvants work? Immunol Lett (2005) 1.53
The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol (2010) 1.45
Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicol Sci (2005) 1.42
Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine (2004) 1.36
H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol (2010) 1.36
Adjuvants designed for veterinary and human vaccines. Vaccine (2001) 1.35
Mechanism of action of licensed vaccine adjuvants. Vaccine (2009) 1.34
Antigen depot is not required for alum adjuvanticity. FASEB J (2011) 1.28
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine (2007) 1.24
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20
Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine (2007) 1.19
Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine (2001) 1.16
Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol (2013) 1.13
Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine (2008) 1.10
Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine (2008) 1.09
Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol (2001) 1.05
Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release (2012) 1.05
Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs (2011) 1.04
Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine (2005) 1.04
Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am (2003) 1.02
Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine (2003) 1.01
Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines. Vaccine (2001) 1.00
Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano (2013) 0.99
Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci (2008) 0.98
Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine (1991) 0.98
Aluminum compounds used as adjuvants in vaccines. Pharm Res (1990) 0.98
In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine (1997) 0.98
Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther (2008) 0.97
Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccin (2009) 0.97
Complement activation by aluminium and zirconium compounds. Immunology (1979) 0.96
Getting closer to the dirty little secret. Immunity (2011) 0.95
A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses (2008) 0.95
Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine (2003) 0.94
Measuring the surface area of aluminum hydroxide adjuvant. J Pharm Sci (2002) 0.94
Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol (2013) 0.94
Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine (2006) 0.93
Future prospects for vaccine adjuvants. Crit Rev Immunol (1988) 0.92
The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins. Vaccine (1999) 0.92
Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine (1996) 0.91
Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol (2011) 0.89
Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol (2006) 0.88
In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine (1996) 0.88
Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants. Vaccine (1994) 0.88
AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines (2008) 0.87
Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine (2001) 0.87
Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice. Immunol Lett (2012) 0.85
The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine (2011) 0.84
Macrophagic myofasciitis associated with vaccine-derived aluminium. Med J Aust (2005) 0.84
Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm Res (1995) 0.84
Adjuvants and inactivated polio vaccine: a systematic review. Vaccine (2012) 0.83
Hepatitis B vaccine. Ann Intern Med (1982) 0.83
The role of the adsorption process for production and control combined adsorbed vaccines. Vaccine (2001) 0.82
Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Vaccine (2005) 0.82
Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity. J Immunol (2013) 0.82
The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm Res (1991) 0.81
Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol (2010) 0.81
Specificity of an anti-aluminium monoclonal antibody toward free and protein-bound aluminium. J Inorg Biochem (1998) 0.79
Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine (2001) 0.79
Mucosal application of cationic poly(D,L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease. Vaccine (2013) 0.78
[Comparison of the kinesis of immune responses in mice vaccinated by different kinds of recombinant hepatitis B vaccines]. Zhonghua Liu Xing Bing Xue Za Zhi (2008) 0.76
[Study on the kinesis of cellular immunity in adults vaccinated with recombinant hepatitis B vaccine]. Zhonghua Liu Xing Bing Xue Za Zhi (2007) 0.76
[Influence of intranasal instilled titanium dioxide nanoparticles on monoaminergic neurotransmitters of female mice at different exposure time]. Zhonghua Yu Fang Yi Xue Za Zhi (2007) 0.76
Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine (2005) 0.76
Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants. J Pharm Pharmacol (2013) 0.76
Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J Pharm Sci (1981) 0.76
CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice. Int Immunopharmacol (2014) 0.76
Adsorption of phosphate by aluminum hydroxycarbonate. J Pharm Sci (1984) 0.76
Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine (1995) 0.76
A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol (2012) 2.81
Picornavirus uncoating intermediate captured in atomic detail. Nat Commun (2013) 1.57
Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine. Virol J (2011) 0.79
Biodegradable polylactide microspheres enhance specific immune response induced by Hepatitis B surface antigen. Hum Vaccin Immunother (2014) 0.75
Application of the hybrid complexation-ultrafiltration process for metal ion removal from aqueous solutions. J Hazard Mater (2008) 0.75